OOIR: Observatory of International Research

Papers

(The H4-Index of Drugs is 56. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Prevention and Treatment of Monkeypox	313
BNT162b2 mRNA COVID-19 Vaccine: First Approval	224
Pharmaco-Immunomodulatory Therapy in COVID-19	191
Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences	174
Inclisiran: First Approval	170
Lumasiran: First Approval	167
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin	167
Remdesivir: First Approval	166
The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update	164
Nirmatrelvir Plus Ritonavir: First Approval	156
Casimersen: First Approval	135
Sacituzumab Govitecan: First Approval	134
Pemigatinib: First Approval	127
Aducanumab: First Approval	114
Viltolarsen: First Approval	114
Sotorasib: First Approval	112
Risdiplam: First Approval	99
Acute Pancreatitis: Diagnosis and Treatment	92
Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update	92
New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma	92
TRPV1-Targeted Drugs in Development for Human Pain Conditions	91
Setmelanotide: First Approval	91
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile I	90
Managing Diabetic Foot Ulcers: Pharmacotherapy for Wound Healing	88
Selpercatinib: First Approval	86

Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis	85
Bulevirtide: First Approval	84
Belantamab Mafodotin: First Approval	83
Remimazolam: First Approval	83
Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ?	83
Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects	80
Pharmacokinetics and Pharmacodynamics of Posaconazole	79
Orelabrutinib: First Approval	79
Inhaled Liposomal Antimicrobial Delivery in Lung Infections	73
New and Emerging Systemic Treatments for Atopic Dermatitis	72
Ozanimod: First Approval	72
Nivolumab Plus Relatlimab: First Approval	72
Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer	71
Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review	69
REGN-EB3: First Approval	68
Selumetinib: First Approval	67
Tirabrutinib: First Approval	67
ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3–5: A Network Meta-Analysis of Randomised Clinical Trials	66
Fabry Disease: The Current Treatment Landscape	66
Lonafarnib: First Approval	66
Amivantamab: First Approval	65
Pralsetinib: First Approval	63
Decitabine/Cedazuridine: First Approval	62
Capmatinib: First Approval	62
HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety	61
Savolitinib: First Approval	60
Belzutifan: First Approval	60
Inebilizumab: First Approval	60
MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19	58
Bempedoic Acid: First Approval	57
Remimazolam: A Review in Procedural Sedation	56
Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations	56
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder	56